Experienced in Systemic Mastocytosis

Dr. Richard M. Schraeder

Hematology Oncology | Hematology | Oncology
University Of Maryland St Joseph Medical Group LLC
7601 Osler Dr, 
Towson, MD 
Accepting New Patients
Experienced in Systemic Mastocytosis
University Of Maryland St Joseph Medical Group LLC
7601 Osler Dr, 
Towson, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Richard Schraeder is a Hematologist Oncology specialist and a Hematologist in Towson, Maryland. Dr. Schraeder is rated as an Experienced provider by MediFind in the treatment of Systemic Mastocytosis. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Small Cell Lung Cancer (SCLC), and Retroperitoneal Liposarcoma. Dr. Schraeder is currently accepting new patients.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Hahneman Medical College Of The Pacific
Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in MD
Hospital Affiliations
University Of Maryland Medical Center
Wellspan York Hospital
The Johns Hopkins Hospital
University Of MD St Joseph Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

UNIVERSITY OF MARYLAND ST JOSEPH MEDICAL GROUP LLC
7601 Osler Dr, Towson, MD 21204

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects With Solid and Hematological Malignancies
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects With Solid and Hematological Malignancies
Enrollment Status: Completed
Publish Date: March 04, 2025
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: April 05, 2023
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
View 4 Less Clinical Trials

1 Total Publications

The changing pathology of lung cancer.
The changing pathology of lung cancer.
Journal: Surgical oncology clinics of North America
Published: October 12, 2011
Similar Doctors
Experienced in Systemic Mastocytosis
Dr. Raymund S. Cuevo
Oncology | Hematology | Hematology Oncology
Experienced in Systemic Mastocytosis
Dr. Raymund S. Cuevo
Oncology | Hematology | Hematology Oncology

Inova Health Care Services

8081 Innovation Park Dr, 
Fairfax, VA 
 (49.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Raymund Cuevo is an Oncologist and a Hematologist in Fairfax, Virginia. Dr. Cuevo is rated as an Advanced provider by MediFind in the treatment of Systemic Mastocytosis. His top areas of expertise are Myelodysplastic Syndrome (MDS), Burkitt Lymphoma, Acute Myeloid Leukemia (AML), Lung Cancer, and Bone Marrow Aspiration. Dr. Cuevo is currently accepting new patients.

Experienced in Systemic Mastocytosis
Dr. Natthapol Songdej
Hematology | Pediatrics | Oncology
Experienced in Systemic Mastocytosis
Dr. Natthapol Songdej
Hematology | Pediatrics | Oncology

The Milton S Hershey Medical Center Physicians Group

500 University Dr, 
Hershey, PA 
 (60.6 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Natthapol Songdej is a Hematologist and a Pediatrics provider in Hershey, Pennsylvania. Dr. Songdej is rated as a Distinguished provider by MediFind in the treatment of Systemic Mastocytosis. His top areas of expertise are RUNX1 Familial Platelet Disorder, Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Acquired Hemophilia, and Bone Marrow Aspiration.

Andrew S. Mener
Experienced in Systemic Mastocytosis
Dr. Andrew S. Mener
Hematology | Hematology Oncology | Oncology
Experienced in Systemic Mastocytosis
Dr. Andrew S. Mener
Hematology | Hematology Oncology | Oncology

Maryland Oncology Hematology

10710 Charter Drive, Suite G020, Suite G020, 
Columbia, MD 
 (19.1 miles away)
410-964-2212
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Andrew Mener, M.D. has experience treating a wide range of adult hematologic and oncologic disorders, with a particular interest in treating breast, lung, gastrointestinal and hematologic malignancies. He takes great pride in delivering personalized, compassionate care and strives to effectively explain complex treatment options to his patients. He strongly believes in the importance of treating each and every patient as an individual. Learn more at marylandoncology.com. Dr. Mener is rated as a Distinguished provider by MediFind in the treatment of Systemic Mastocytosis. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Iron Deficiency Anemia, and Severe Congenital Neutropenia.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Schraeder's expertise for a condition
ConditionClose
    View All 20 Distinguished Conditions
    View All 41 Advanced Conditions
    View All 76 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile